INTERVIEW
Lupin has emphasized the development of biosimilars for regulated markets. Could you elaborate on the progress and future plans in this area?
We have made significant strides in developing biosimilars for regulated markets, with a clear focus on expanding our global presence. We have successfully obtained regulatory approvals for several biosimilars in key markets. For instance, biosimilar Pegfilgrastim( Armlupeg ®) received approval from Health Canada in 2024. Additionally, our Etanercept biosimilar( Nepexto ®) has been launched in 20 + countries globally, including highly regulated markets including EU, Japan and Canada.
We will continue to expand our product portfolio with the filing of Marketing Authorization for three biosimilars in regulated markets in 2025 and 2026. We also have an early phase pipeline of 5-6 products, slated for clinical development and launch in next 4-5 years. By leveraging its costeffective manufacturing capabilities and strategic partnerships, our mission
is to enhance access to high-quality, affordable biologics worldwide. We will also differentiate our product offering through the development of next generation devices and enhancing our core capabilities across the value chain. Drawing inspiration from evolving regulatory guidelines and early scientific advises, we shall continue to optimize clinical trial requirements to enhance the development cost and time for next wave of Biosimilars.
In addition to being a Biosimilar player, we also provide our clientele with CDMO services for custom Research and Manufacturing. Our state-of-the-art manufacturing & research infrastructure, skilled talent pool and relevant expertise makes us a trusted partner of choice in the biotech CDMO space.
What is your vision and broader plan for this startup in the next 5 years?
In the next five years, we aim to establish ourselves as the country ' s first company offering comprehensive longevity solutions. Our vision is to provide an integrated package that includes translational machine learning-based risk prediction, diagnostic and longevity markers, and therapeutic solutions. We want to make these solutions accessible to people interested in longevity while generating sustainable revenue through our innovative approach to healthy aging.
30
BioVoiceNews | April 2025